BMS’ Andreotti Talks BD Beyond 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncology, virology and cardiovascular remain top therapeutic priorities in mid-term, but longer term focus at BMS is shifting to oncology, CNS and cardiovascular and metabolic diseases, CEO Lamberto Andreotti tells analysts at Sanford F. Bernstein conference.